Literature DB >> 4005117

In vitro and in vivo deconvolution assessment of drug release kinetics from oxprenolol Oros preparations.

F Langenbucher, J Mysicka.   

Abstract

The relationship between in vitro and in vivo drug release from Oros systems has been examined by analysing plasma concentration data from two pharmacokinetic studies, using a numerical deconvolution technique. This method generates an input profile by comparing the response with that achieved following an instantaneous reference unit dose. The approach is conceptually simple and does not require compartmental pharmacokinetic modelling or curve fitting. In the analysis of the first study, the plasma profile following intravenous dosing was used as the reference function, allowing the combined release/absorption process to be calculated; for the second, an oral bolus was used, the result of the deconvolution therefore indicating the in vivo dissolution rate of the Oros systems. The in vivo release from Oros in most volunteers followed the same pattern as that measured in vitro; only after 6-8 h was the decline in the in vivo release rate somewhat greater than expected. In a few individuals the cumulative absorption profile reached an early plateau level which coincided, on some but not all occasions, with the premature excretion of the Oros system from the body. The amount of drug in recovered systems agreed reasonably with the prediction of the deconvolution analysis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4005117      PMCID: PMC1463757          DOI: 10.1111/j.1365-2125.1985.tb02756.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Elementary osmotic pump.

Authors:  F Theeuwes
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Pharmacokinetics of oxprenolol in normal subjects.

Authors:  W D Mason; N Winer
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

3.  A new numerical calculation method for deconvolution in linear compartment analysis of pharmacokinetics.

Authors:  H Kiwada; K Morita; M Hayashi; S Awazu; M Hanano
Journal:  Chem Pharm Bull (Tokyo)       Date:  1977-06       Impact factor: 1.645

4.  Studies on absorption and excretion of drug. VII. A new estimation method for the release of drugs from dosage forms and the availability in vivo.

Authors:  M Hanano
Journal:  Chem Pharm Bull (Tokyo)       Date:  1967-07       Impact factor: 1.645

5.  Mathematical basis of point-area deconvolution method for determining in vivo input functions.

Authors:  D P Vaughan; M Dennis
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

6.  Assessment of rate and extent of drug absorption.

Authors:  D Cutler
Journal:  Pharmacol Ther       Date:  1981       Impact factor: 12.310

7.  Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration.

Authors:  F Theeuwes; D R Swanson; G Guittard; A Ayer; S Khanna
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

8.  Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release.

Authors:  I D Bradbrook; V A John; P J Morrison; H J Rogers; R G Spector
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

9.  Oxprenolol absorption in man after single bolus dosing into two segments of the colon compared with that after oral dosing.

Authors:  K H Antonin; P Bieck; M Scheurlen; M Jedrychowski; H Malchow
Journal:  Br J Clin Pharmacol       Date:  1985       Impact factor: 4.335

  9 in total
  1 in total

1.  Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy.

Authors:  S S Davis; N Washington; G D Parr; A H Short; V A John; P Lloyd; S M Walker
Journal:  Br J Clin Pharmacol       Date:  1988-10       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.